StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price target on shares of Oncternal Therapeutics in a report on Tuesday, July 16th.

Oncternal Therapeutics Stock Performance

Shares of ONCT stock opened at $5.74 on Wednesday. The company has a market capitalization of $16.99 million, a PE ratio of -0.47 and a beta of 1.36. The firm has a fifty day simple moving average of $7.44 and a 200-day simple moving average of $8.38. Oncternal Therapeutics has a twelve month low of $5.09 and a twelve month high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($2.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.88) by $0.05. The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.18 million. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. During the same period in the prior year, the company posted ($4.00) earnings per share. Equities research analysts predict that Oncternal Therapeutics will post -11.63 EPS for the current year.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 16.05% of the stock is currently owned by institutional investors and hedge funds.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.